Vanguard Group Inc made a significant addition to its portfolio by acquiring 9,018,094 shares of Edwards Lifesciences Corp ...

IntroductionThe prosthetic heart valves market has witnessed significant transformation over the past few decades, driven by ...

Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $67 per share, about 50% lower than the peak level of $131 seen in December ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.0, with a high ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural ...

Edwards Lifesciences Corporation (EW), headquartered ... the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.

Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive ...

The Galien Foundation recently announced the nominees for its "Best Medical Technology" Pix Galien USA awards.

Edwards Lifesciences ... the company is now focused on its heart disease business. In the last 12 months, the following revenues were generated: Transcatheter Aortic Valve Replacement Revenue ...

Pi-Cardia designed the Shortcut device to mitigate the risk of coronary artery obstruction by splitting aortic valve leaflets ...